CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
Oral [14C]PF-06865571 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04866225
NCT04866225Phase 1Completed
CompareCT.gov

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE EXTENT OF EXCRETION, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06865571 USING A 14C-MICROTRACER APPROACH

Pfizer·interventional·Posted Apr 29, 2021·Updated Jul 31, 2024

In Brief

A Phase 1 clinical trial evaluating Oral [14C]PF-06865571, Oral PF-06865571, and 1 other intervention for Healthy Participants. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of \[14C\]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of \[14C\]PF-06865571.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedApr 29, 2021
Enrollment StartMay 11, 2021
Primary CompletionJul 11, 2021
Study CompletionAug 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.2 years ago

Interventions

Oral [14C]PF-06865571drug

Oral radiolabeled PF-06865571

Oral PF-06865571drug

Oral PF-06865571

IV [14C]PF-06865571drug

IV radiolabeled PF-06865571